COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy

Hepatology. 2021 Aug;74(2):1074-1080. doi: 10.1002/hep.31728. Epub 2021 Jul 26.

Authors

Giovanni Sansoè¹, Manuela Aragno², Florence Wong³

Affiliations

¹ Division of GastroenterologyHumanitas InstituteGradenigo HospitalTorinoItaly.
² Department of Clinical and Biological SciencesUniversity of TorinoTorinoItaly.
³ Department of MedicineUniversity of TorontoToronto General HospitalTorontoOntarioCanada.

Abstract

Publication types

Review

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme 2 / genetics
Angiotensin-Converting Enzyme 2 / metabolism
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
COVID-19 / enzymology
COVID-19 / therapy
COVID-19 / virology*
Genetic Therapy
Humans
Liver / enzymology*
Liver / physiopathology
Liver / virology
Liver Cirrhosis / enzymology*
Liver Cirrhosis / therapy
Liver Cirrhosis / virology
Renin-Angiotensin System / physiology*
SARS-CoV-2 / pathogenicity*

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin-Converting Enzyme 2